An official website of the United States government

Quadramet

PubChem CID
6918027
Structure
Quadramet_small.png
Quadramet_3D_Structure.png
Molecular Formula
Synonyms
  • Quadramet
  • Samarium Sm 153 lexidronam
  • Lexidronam Sm 153
  • Sm-153-EDTMP
  • SHR-3644
Molecular Weight
589.05 g/mol
Computed by PubChem 2.1 (PubChem release 2021.05.07)
Parent Compound
Dates
  • Create:
    2006-07-28
  • Modify:
    2025-01-25

1 Structures

1.1 2D Structure

Chemical Structure Depiction
Quadramet.png

1.2 3D Conformer

3D Conformer of Parent

2 Names and Identifiers

2.1 Computed Descriptors

2.1.1 IUPAC Name

[2-[bis(phosphonomethyl)amino]ethyl-(phosphonomethyl)amino]methylphosphonic acid;samarium-153
Computed by LexiChem 2.6.6 (PubChem release 2019.06.18)

2.1.2 InChI

InChI=1S/C6H20N2O12P4.Sm/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20;/h1-6H2,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20);/i;1+3
Computed by InChI 1.0.5 (PubChem release 2019.06.18)

2.1.3 InChIKey

WNYXBFNBLZLWRA-GJNDDOAHSA-N
Computed by InChI 1.0.5 (PubChem release 2019.06.18)

2.1.4 SMILES

C(CN(CP(=O)(O)O)CP(=O)(O)O)N(CP(=O)(O)O)CP(=O)(O)O.[153Sm]
Computed by OEChem 2.3.0 (PubChem release 2024.12.12)

2.2 Molecular Formula

C6H20N2O12P4Sm
Computed by PubChem 2.1 (PubChem release 2019.06.18)

2.3 Synonyms

2.3.1 MeSH Entry Terms

  • 153Sm-EDTMP
  • Quadramet
  • samarate(5-)-153Sm, (((1,2-ethanediylbis((nitrilo-kappa-N)bis(methylene)))tetrakis(phosphonato-kappa-O))(8-))-, pentahydrogen, (oc-6-21)
  • samarium (153Sm) lexidronam
  • samarium ethylenediaminetetramethylenephosphonate
  • samarium Sm-153 lexidronam
  • samarium-153 lexidronam
  • samarium-153-EDTMP
  • Sm-EDTMP

2.3.2 Depositor-Supplied Synonyms

3 Chemical and Physical Properties

3.1 Computed Properties

Property Name
Molecular Weight
Property Value
589.05 g/mol
Reference
Computed by PubChem 2.1 (PubChem release 2021.05.07)
Property Name
Hydrogen Bond Donor Count
Property Value
8
Reference
Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Property Name
Hydrogen Bond Acceptor Count
Property Value
14
Reference
Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Property Name
Rotatable Bond Count
Property Value
2
Reference
Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Property Name
Exact Mass
Property Value
588.91878 Da
Reference
Computed by PubChem 2.1 (PubChem release 2021.05.07)
Property Name
Monoisotopic Mass
Property Value
588.91878 Da
Reference
Computed by PubChem 2.1 (PubChem release 2021.05.07)
Property Name
Topological Polar Surface Area
Property Value
237 Ų
Reference
Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Property Name
Heavy Atom Count
Property Value
25
Reference
Computed by PubChem
Property Name
Formal Charge
Property Value
0
Reference
Computed by PubChem
Property Name
Complexity
Property Value
586
Reference
Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Property Name
Isotope Atom Count
Property Value
1
Reference
Computed by PubChem
Property Name
Defined Atom Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Undefined Atom Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Defined Bond Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Undefined Bond Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Covalently-Bonded Unit Count
Property Value
2
Reference
Computed by PubChem
Property Name
Compound Is Canonicalized
Property Value
Yes
Reference
Computed by PubChem (release 2019.01.04)

3.2 Chemical Classes

3.2.1 Drugs

3.2.1.1 Human Drugs
Breast Feeding; Lactation; Radiopharmaceuticals; Samarium Radioisotopes
Human drug -> Discontinued
Human drugs -> Therapeutic radiopharmaceuticals -> Human pharmacotherapeutic group -> EMA Drug Category

5 Chemical Vendors

6 Drug and Medication Information

6.1 Drug Indication

Quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium [99mTc]-labelled biphosphonates on bone scan. The presence of osteoblastic metastases which take up technetium [99mTc]-labelled biphosphonates should be confirmed prior to therapy.

6.2 Drug Classes

Breast Feeding; Lactation; Radiopharmaceuticals; Samarium Radioisotopes

6.3 Clinical Trials

6.3.1 EU Clinical Trials Register

6.4 EMA Drug Information

Medicine
Category
Human drugs
Therapeutic area
Pain; Cancer
Active Substance
INN/Common name
samarium [153Sm] lexidronam pentasodium
Pharmacotherapeutic Classes
Therapeutic radiopharmaceuticals
Status
This medicine is authorized for use in the European Union
Company
CIS bio international
Market Date
1998-02-04

7 Pharmacology and Biochemistry

7.1 MeSH Pharmacological Classification

Analgesics, Non-Narcotic
A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)

7.2 ATC Code

V10BX02

8 Use and Manufacturing

8.1 Uses

8.1.1 Use Classification

Human drugs -> Therapeutic radiopharmaceuticals -> Human pharmacotherapeutic group -> EMA Drug Category

9 Toxicity

9.1 Toxicological Information

9.1.1 Effects During Pregnancy and Lactation

◉ Summary of Use during Lactation

Information in this record refers to the use of samarium Sm 153 lexidronam pentasodium as a therapeutic agent. No information is available on the use of samarium Sm 153 lexidronam pentasodium during breastfeeding. Most conditions treated with samarium Sm 153 would not occur in mothers wishing to nurse. However, the manufacturer recommends not administering the drug in women who wish to continue breastfeeding. Because of the relatively long half-life of samarium 153, the standard waiting period of 10 half-lives would be close to 3 weeks which might be impractical for resuming breastfeeding. The manufacturer and expert opinion recommend discontinuing breastfeeding if the agent is administered.

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at background levels they may safely resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.

◉ Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

◉ Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

10 Literature

10.1 Consolidated References

10.2 NLM Curated PubMed Citations

10.3 Chemical Co-Occurrences in Literature

10.4 Chemical-Gene Co-Occurrences in Literature

10.5 Chemical-Disease Co-Occurrences in Literature

11 Patents

11.1 Chemical Co-Occurrences in Patents

11.2 Chemical-Disease Co-Occurrences in Patents

11.3 Chemical-Gene Co-Occurrences in Patents

12 Classification

12.1 MeSH Tree

13 Information Sources

  1. Drugs and Lactation Database (LactMed)
    Samarium Sm 153 Lexidronam Pentasodium
    https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM1130/
  2. Drugs@FDA
    LICENSE
    Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
    https://www.fda.gov/about-fda/about-website/website-policies#linking
  3. European Medicines Agency (EMA)
    LICENSE
    Information on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.
    https://www.ema.europa.eu/en/about-us/legal-notice
  4. EU Clinical Trials Register
  5. PubChem
  6. Medical Subject Headings (MeSH)
    LICENSE
    Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.
    https://www.nlm.nih.gov/copyright.html
CONTENTS